UQ1.F uniQure N.V

Healthcare Biotechnology Frankfurt Exchange
21.90 EUR
Close of Nov 13, 2026
7.26 43.90
Market cap
EUR 1.54B
P/E
-
P/B
5.77x
ROE
-88.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is UQ1.F undervalued?

Graham number

The Graham number of uniQure N.V cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

uniQure N.V fundamental analysis

No fundamental analysis for uniQure N.V yet.

uniQure N.V stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About uniQure N.V

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the …

Full company profile